PUMA BIOTECHNOLOGY, INC. Asset Impairment Charges
PUMA BIOTECHNOLOGY, INC. (PBYI) reported Asset Impairment Charges of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AssetImpairmentCharges · last filed 2026-02-26
- PUMA BIOTECHNOLOGY, INC. asset impairment charges for the quarter ending 2024-12-31 was $0.00.
- PUMA BIOTECHNOLOGY, INC. asset impairment charges for the quarter ending 2023-12-31 was $0.00.
- PUMA BIOTECHNOLOGY, INC. asset impairment charges for the quarter ending 2022-12-31 was $0.00.
- PUMA BIOTECHNOLOGY, INC. asset impairment charges for fiscal 2025 was $0.00.
- PUMA BIOTECHNOLOGY, INC. asset impairment charges for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- PUMA BIOTECHNOLOGY, INC. asset impairment charges for fiscal 2023 was $625.00K.
- PUMA BIOTECHNOLOGY, INC. asset impairment charges for fiscal 2022 was $0.00.
| Period end | Asset Impairment Charges 3 month | Asset Impairment Charges 9 month | Asset Impairment Charges 12 month |
|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-26 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 | |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-07 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $625.00K 10-K · filed 2026-02-26 | |
| 2023-09-30 | $625.00K 10-Q · filed 2024-11-07 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $0.00 10-K · filed 2025-02-27 | |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-02 | ||
| 2021-12-31 | $0.00 10-K · filed 2024-02-29 | ||
| 2020-12-31 | $0.00 10-K · filed 2022-03-03 | ||
| 2019-12-31 | $1.18M 10-K · filed 2022-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |